CADTH | pCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

PROVINCIAL FUNDING SUMMARY

Avelumab (Bavencio) for metastatic Merkel Cell Carcinoma (pCODR 10124)

pERC Recommendation: Recommends with conditions

For further details, please see pERC Final Recommendation

Notification to Implement Issued by pCODR: April 6, 2018

This information is current as of November 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	May 1, 2019	Recurrent or metastatic Merkel cell carcinoma following progression of disease after first-line chemotherapy with SMMCCPE • Patients are eligible to receive first-line if a contraindication to SMMCCPE exists • ECOG 0 - 2 • Adequate hematologic and biochemical laboratory test results • Access to a treatment centre with expertise to manage immune-mediated adverse reactions of avelumab • BC Cancer Agency Compassionate Access Program (CAP) approval must be obtained.
AB	Funded	Oct 7, 2019	For the treatment of metastatic Merkel cell carcinoma (mMCC) in adults who have had prior cytotoxic chemotherapy, or in patients who are ineligible for cytotoxic chemotherapy. Treatment should continue until confirmed disease progression or unacceptable toxicity. For patients who achieve a complete response (CR), treatment should continue for a maximum of 12 months after confirmation of CR.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
SK	Funded	May 1, 2019	• Treatment of metastatic Merkel Cell carcinoma (mMCC) in previously treated adults with good performance status who have had prior cytotoxic chemotherapy. • Treatment of metastatic Merkel Cell carcinoma (mMCC) in adults with good performance status who are ineligible for treatment with cytotoxic chemotherapy (e.g., contraindications for treatment with cytotoxic chemotherapy) and who would not be able to receive first-line chemotherapy. • Treatment may continue until confirmed disease progression or unacceptable toxicity; for patients who achieve a complete response (CR), treatment should continue for a maximum of 12 months after confirmation of CR.
MB	Funded	Feb 14, 2019	Treatment of metastatic Merkel Cell Carcinoma in previously treated adults with good performance status who have had prior cytotoxic chemotherapy or, Treatment of metastatic Merkel Cell Carcinoma in adults with good performance status who are ineligible for treatment with cytotoxic chemotherapy (eg., contraindications for treatment with cytotoxic chemotherapy) and who would not be able to receive first-line chemotherapy. Treatment should continue until confirmed disease progression or unacceptable toxicity. For patients who achieve a complete response (CR), treatment should continue for a maximum of 12 months after confirmation of CR.
ON	Funded	Apr 18, 2019	Avelumab is used for the treatment of previously treated adult patients with metastatic Merkel cell carcinoma who have good performance status and have had prior cytotoxic chemotherapy or • Avelumab is used for the treatment of adult patients with metastatic Merkel cell carcinoma who have good performance status and are ineligible for treatment with cytotoxic chemotherapy (e.g., contraindications to treatment with cytotoxic chemotherapy). • Treatment should continue until confirmed disease progression or unacceptable toxicity. For patients who achieve a complete response (CR), treatment should continue for a maximum of 12 months after confirmation of CR. • Avelumab funding is for single agent use only. • Patients who have a confirmed CR and relapse after stopping treatment are allowed one re-initiation of treatment if the treating physician deems the patient eligible for retreatment. Claims should be submitted under the same form used for initial treatment.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NS	Funded	Oct 3, 2019	For the treatment of adult patients with metastatic Merkel Cell Carcinoma who have received prior cytotoxic chemotherapy or, who are ineligible to receive first-line cytotoxic chemotherapy, (e.g. contraindications for treatment with cytotoxic chemotherapy). Patients must have a good performance status. Treatment should be discontinued upon confirmed disease progression or unacceptable toxicity. For patients who achieve a complete response (CR), treatment should continue for a maximum of 12 months after confirmation of CR.
NB	Funded	Jul 24, 2019	For the treatment of adult patients with metastatic Merkel cell carcinoma who have received prior cytotoxic chemotherapy or who are ineligible (i.e., due to contraindications) to receive first-line cytotoxic chemotherapy. Patients must have a good performance status. Treatment should be discontinued upon confirmed disease progression or unacceptable toxicity. For patients who achieve a complete response (CR), treatment should continue for a maximum of 12 months after confirmation of CR.
NL	Funded	Aug 26, 2019	Single-agent treatment of metastatic Merkel Cell carcinoma in • Previously treated adults with good performance status who have had prior cytotoxic chemotherapy, or • Previously untreated adults with good performance status who have a contraindication to cytotoxic chemotherapy Treatment should continue until disease progression, unacceptable toxicity, or a maximum of 12 months after confirmation of complete response.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.